当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2013年, 第13卷, 第2期, 第81-84页
标题:
心血管疾病患者肥胖症的药物治疗研究进展
DOI:
10.5428/pcar20130201
作者:
1. 陈亮(第二军医大学长海医院心血管内科 上海 200433 chenliangsmmu@163.com)
2. 白元(第二军医大学长海医院心血管内科 上海 200433 )
3. 秦永文(第二军医大学长海医院心血管内科 上海 200433 qyw2009@163.com)
摘要:
摘要  肥胖症与2型糖尿病、高血压、血脂异常及心血管病等多种疾病密切相关。目前,肥胖症药物治疗的研究方向主要是针对身体质量指数(BMI)>30 kg/m2或BMI>27 kg/m2且患有其他合并症的严重肥胖症患者。但药物的副作用及有关安全性和有效性长期证据的缺乏限制了其使用。本文对治疗肥胖症药物的作用机制、疗效及其对心血管风险的影响作一综述。
欢迎阅读《药学服务与研究》!您是该文第 1553 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 陈亮,白元,秦永文. 心血管疾病患者肥胖症的药物治疗研究进展[J]. 药学服务与研究. 2013; 13(2): 81-84.
英文著录格式 CHEN Liang,BAI Yuan,QIN YongWen. Research advances in drug treatment of obesity patients with cardiovascular diseases[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2013; 13(2): 81-84.
参考文献:
1. Cannon C P. Obesity-related cardiometabolic complications[J]. Clin Cornerstone, 2008,9(1):11-19; discussion 20-22.
2. Singh P,Peterson T E,Barber K R,et al. Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascularendothelial cells[J]. Biochem Biophys Res Commun, 2010,392(1):47-52.
3. Mangge H,Almer G,Truschnig-Wilders M,et al. Inflammation, adiponectin, obesity and cardiovascular risk[J]. Curr Med Chem, 2010,17(36):4511-4520.
4. Azekoshi Y,Yasu T,Watanabe S,et al. Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin Ⅱ production in mononuclear and polymorphonuclear cells[J]. Hypertension,2010,56(1):136-142.
5. Rahmouni K,Correia M L,Haynes W G,et al. Obesity-associated hypertension: new insights into mechanisms[J]. Hypertension, 2005,45(1):9-14.
6. Morgan D A,Thedens D R,Weiss R,et al. Mechanisms mediating renal sympathetic activation to leptin in obesity[J]. Am J Physiol Regul Integr Comp Physiol, 2008,295(6):R1730-R1736.
7. Cannon C P,Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options[J]. Clin Cornerstone, 2009,9(4):55-68; discussion 69-71.
8. Napolitano A,Murgatroyd P R,Finer N,et al. Assessment of acute and chronic pharmacological effects on energy expenditure and macronutrient oxidation in humans: responses to ephedrine[J]. J Obes,2011,pii:210484.
9. Ledford H. Slim spoils for obesity drugs[J]. Nature, 2010,468(7326):878.
10. Acharya N V,Wilton L V,Shakir S A. Safety profile of orlistat: results of a prescription-event monitoring study[J]. Int J Obes(Lond),2006,30(11):1645-1652.
11. Berne C,Orlistat Swedish Type 2 Diabetes Study Group.A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin[J]. Diabet Med, 2005,22(5):612-618.
12. Torgerson J S,Hauptman J,Boldrin M N,et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients[J]. Diabetes Care, 2004,27(1):155-161.
13. de Castro J J,Dias T,Chambel P,et al. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia[J]. Rev Port Cardiol,2009,28(12):1361-1374.
14. Derosa G,Cicero A F,D’Angelo A,et al. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes[J]. J Clin Pharm Ther, 2012,37(2):187-195.
15. Hendricks E J,Greenway F L,Westman E C,et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity[J]. Obesity (Silver Spring), 2011,19(12):2351-2360.
16. Wilding J,Van Gaal L,Rissanen A,et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects[J]. Int J Obes Relat Metab Disord, 2004,28(11):1399-1410.
17. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy (‘sick fat’) and metabolic disease[J]. Expert Rev Cardiovasc Ther, 2010,8(12):1777-1801.
18. Smith S R,Weissman N J,Anderson C M,et al. Multicenter, placebo-controlled trial of lorcaserin for weight management[J]. N Engl J Med,2010,363(3):245-256.
19. Anon.New weight-loss drugs and the US obesity epidemic[J].Lancet, 2012,380(9839):308.
20. Hurren K M,Berlie H D.Lorcaserin: an investigational serotonin 2C agonist for weight loss[J]. Am J Health Syst Pharm,2011,68(21):2029-2037.
21. Greenway F L,Fujioka K,Plodkowski R A,et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-Ⅰ): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2010,376(9741):595-605.
22. Gadde K M,Allison D B,Ryan D H,et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011,377(9774):1341-1352.
23. Schramm T K,Gislason G H,Vaag A,et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study[J]. Eur Heart J, 2011,32(15):1900-1908.
24. Fontbonne A, Diouf I, Baccara-Dinet M,et al. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial[J]. Diabetes Metab, 2009,35(5):385-391.
25. Buse J B,Drucker D J,Taylor K L,et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks[J]. Diabetes Care, 2010,33(6):1255-1261.
26. Astrup A,Carraro R,Finer N,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide[J]. Int J Obes (Lond), 2012,36(6):843-854.
27. Okerson T,Chilton R J. The cardiovascular effects of GLP-1 receptor agonists[J]. Cardiovasc Ther, 2012,30(3):e146-e155.
28. James W P,Caterson I D,Coutinho W,et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects[J]. N Engl J Med,2010,363(10):905-917.
29. Coutinho T,Goel K,Corrêa de S D,et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data[J]. J Am Coll Cardiol,2011,57(19):1877-1886.